C-5W6Qallogeneic cell therapy, directed differentiation, pluripotent cells
0-100 chain-logic scale · 15 dimensions · scored on public evidence
The DOSED clinical study evaluates the safety and utility of a novel delivery device to deliver LCTOPC1, a cell therapy, to the spinal cord of patients with a spinal cord injury (SCI). LCTOPC1 is designed to replace or support cells that are absent or dysfunctional due to traumatic injury, with a goal to help improve the quality of life and restore or augment functional activity in persons suffering from a traumatic cervical or thoracic injuries.
This is a LTFU study for cervical SCI subjects that were administered AST-OPC1 cells in the main study AST-OPC1-01.
The purpose of this study is to evaluate the safety of cross sequential escalating doses of AST-OPC1 administered among 5 cohorts at a single time-point between 21 and 42 days post injury, inclusively, to subjects with subacute cervical spinal cord injuries (SCI).
This is a LTFU study for thoracic SCI subjects that were administered GRNOPC1 cells in the main study CP35A007.
The purpose of the study is to evaluate the safety of GRNOPC1 administered at a single time-point between 7 and 14 days post injury, inclusive, to patients with neurologically complete spinal cord injuries (SCI).
Lineage - 2026 Company Profile, Team, Funding, Competitors & Financials - Tracxn JavaScript is disabled in your browser. enable it to enjoy the full features of Tracxn. Your browser was unable to load all of Tracxn resources. They may have been blocked by your firewall, proxy or browser configuration. Press Ctrl+F5 or Ctrl+Shift+R to have your browser try again and if that doesn't work, click here to retry or mail us at [email protected] Internal Server Error Toggle navigation Customers Investment Industry Venture Capital Funds Private Equity Funds Accelerators & Incubators Investment … ares Acquired by Andra AP fonden MarketBeat • Feb 28, 2026 • AMETEK , Second AP Fund , Barclays , Lineage and 1 other • Lineage reports Q4 results Seeking Alpha • Feb 25, 2026 • Lineage • HighTower Advisors LLC Makes New Investment in Lineage, Inc. $LINE MarketBeat • Feb 18, 2026 • Lineage , High Tower • Mytra Secures $120 Million Series C to Expand Supply Chain Operating System Pulse 2.0 • Jan 15, 2026 • Kivu Ventures , Mytra , Avenir Growth Capital , Liquid 2 Ventures and 9
Lineage Takes Delivery of Gene-edited Hypoimmune Cell Line Under Partnership With Factor Bioscience - Factor Bioscience Science Technology Presentations and Publications Patents Pipeline Partners About News Contact Lineage Takes Delivery of Gene-edited Hypoimmune Cell Line Under Partnership With Factor Bioscience January 6, 2026 CARLSBAD, Calif.–(BUSINESS WIRE)– Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf,” cell therapies for serious medical conditions, today announced the rece … Scientist Job Type: Full-Time Job Duration: Indefinite Min Education: Master’s Apply for this job First name * Last name * Email * Phone * Do you currently reside within the Continental United States or Canada? Select... Yes No How active are you in your job search? Are you able to work in the Boston area or are you willing to relocate for this position? Select... Yes No What about this role inspired you to apply? When would you be able to start a new position? Resume Upload … 5MB Cover Letter Upload a file or drag and drop. pdf, rtf, doc, docx up to 5MB Submit application Franklin Kostas Associate Scientist Realizing Achievement and Direction through His Research Franklin Kostas joined one of Factor Bioscience’s spinoffs, Novellus Therapeutics, as an Associate Scientist after graduating with a Bachelor of Science degree in chemistry from Haverford College in 2018. Many from his graduating class went straight into graduate school or took technicia … lly will increase their efforts,” he said. “That’s something that I’ve tried to apply to other parts of my life.” A Discovery at the Interface of Chemistry and Biology Franklin designed and executed many rounds of experiments using both panels of lipid and polymer-based reagents that he selected for this purpose as well as molecules that he designed and synthesized himself. His results led him to develop a family of novel chemical substances, including a group of ionizable fu … in chemistry and biology at the Robert College of Istanbul. He received a full scholarship to Ohio Wesleyan University and graduated with a degree in Biochemistry before going on to complete a Ph.D. in Biochemistry and Molecular Biophysics at the California Institute of Technology in computational enzyme design. As a Postdoctoral Research Associ
NOVA Coldstore has been Acquired by Lineage | TM Capital. Success. Realized | Greg Berube LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedI
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
Lineage Acquires Entrepôt Congelé 10/35, Enhances Canadian Presence | Seven Lakes Partners posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join
Lineage | Our heritage and history Skip to Main Navigation Skip to Main Content Skip to Footer Links Team Resources Customer Login Lineage Link® Contact Us Search Language Search Language Lineage ABOUT US Heritage Leadership Case Studies Foundation for Good Cold Chain 101 Innovation & Technology Sustainability Inclusive Culture Lineage Ventures SERVICES Global Warehousing Cold Storage Warehousing Port-Centric Warehousing Automated Warehousing Built-to-Suit Warehousing Sustainable Warehousing Fresh & Perishable Solutions Food Processing & Manufacturing Supply Chain Engineering Globa … ence at the Port of Bellingham. 2025 Lineage Announces 2024 Carrier of the Year Award Winners Lineage recognized top-performing transportation partners across eight categories in its 2024 Carrier of the Year awards, honoring excellence in truckload, LTL, and drayage services. 2025 Lineage to Expand U.S. Network with Tyson Foods Partnership Lineage announced plans to acquire four cold storage warehouses from Tyson Foods and build two fully automated facilities to expand its U. … ence at the Port of Bellingham. 2025 Lineage Announces 2024 Carrier of the Year Award Winners Lineage recognized top-performing transportation partners across eight categories in its 2024 Carrier of the Year awards, honoring excellence in truckload, LTL, and drayage services. 2025 Lineage to Expand U.S. Network with Tyson Foods Partnership Lineage announced plans to acquire four cold storage warehouses from Tyson Foods and build two fully automated facilities to expand its U.
Lineage Cell Therapeutics Issues Letter to Stockholders | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
Modernizing Finance Without Lo…–CFO Weekly – Apple Podcasts Search Home New Top Charts Search 16 June 21 min Modernizing Finance Without Losing the Human Element CFO Weekly Play In this episode of CFO Weekly , Jill Howe, Chief Financial Officer at Lineage Cell Therapeutics, joins Megan Weis to explore how finance leaders can modernize their teams through technology while keeping people at the center of transformation. Lineage Cell Therapeutics is a biotech company developing innovative cell therapies for conditions including spinal cord injury, age-related macular degeneration. Jill brings mor
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
Large-scale analysis reveals acquisition of lineage-specific chromosomal aberrations in human adult stem cells Large-scale analysis reveals acquisition of lineage-specific chromosomal aberrations in human adult stem cells Cell Stem Cell . 2011 Aug 5;9(2):97-102. doi: 10.1016/j.stem.2011.06.013. Authors Uri Ben-David 1 , Yoav Mayshar , Nissim Benvenisty Affiliation 1 Stem Cell Unit, Department of Genetics, Silberman Institute of Life Sciences, The Hebrew University of Jerusalem, 91904, Israel. PMID: 21816361 DOI: 10.1016/j.stem.2011.06.013 Abstract In this study, we assessed
Perishable Shipping Solutions Acquired by Lineage Logistics – SJF Ventures SJF Entrepreneurs Home Portfolio Impact News & Insights All Financings Portfolio Insights Case Studies Archive 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 Perishable Shipping Solutions Acquired by Lineage Logistics Novi, MI – June 7, 2022 – Lineage Logistics, LLC (“Lineage” or the “Company”), the world’s largest and most innovative temperature-controlled industrial REIT and logistics solutions provider, today announced that it is expanding its Direct-to-Consumer (“D2C”
line-20250425 0001868159 DEF 14A false iso4217:USD xbrli:pure 0001868159 2024-01-01 2024-12-31 0001868159 ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember ecd:PeoMember 2024-01-01 2024-12-31 0001868159 ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember ecd:PeoMember 2024-01-01 2024-12-31 0001868159 ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember ecd:PeoMember 2024-01-01 2024-12-31 0001868159 ecd:VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember ecd:PeoMember 2024-01-01 2024-12-31 0001868159 ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember ecd:PeoMember 2024-0 … ment, if Other Than the Registrant) Payment of Filing Fee (Check all boxes that apply): ☒ No fee required. ☐ Fee paid previously with preliminary materials: ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. April 28, 2025 Dear Fellow Shareholders, Looking back on 2024, it’s clear this has been a transformational year for Lineage, Inc. – one that not only strengthened our leadership in the … sure proper representation of your shares at the Annual Meeting, we urge you to submit your proxy voting instructions. To be admitted to the virtual Annual Meeting, you will need to log in to www.proxyvote.com using the control number found in the Notice Regarding the Availability of Proxy Materials, proxy card or voting instruction form. The Annual Meeting will begin promptly at 1:00 p.m., Eastern Daylight Time, on June 18, 2025. Online access to the webcast will open a … , on or about April 28, 2025. TABLE OF CONTENTS Page GENERAL INFORMATION 1 PROPOSAL 1: ELECTION OF DIRECTORS 5 PROPOSAL 2: RATIFICATION OF APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM 10 INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FEES AND OTHER MATTERS 12 AUDIT COMMITTEE REPORT 13 PROPOSAL 3: ADVISORY (NON-BINDING) APPROVAL OF THE COMPENSATION OF THE COMPANY’S NAMED EXECUTIVE OFFICERS 14 PROPOSAL 4: ADVISORY (NON-BINDING) APPROVAL OF THE FREQUENC … ted to physically attend the Annual Meeting. During the Annual Meeting, you may submit questions and vote your shares electronically. What items will be voted on at the Annual Meeting, and how does the Board recommend that I vote? The purpose of the Annual Meeting is to vote on the following items described in this proxy statement: • Propos
Access Denied Access Denied You don't have permission to access "http://www.businesswire.com/AK_PM_VPATH1/714432/bw_maintenance.html" on this server. Reference #18.ccb31402.1782537476.8db8afe https://errors.edgesuite.net/18.ccb31402.1782537476.8db8afe
Lineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
Lineage | Acquisition Expands US Cold Storage Network Skip to Main Navigation Skip to Main Content Skip to Footer Links Team Resources Customer Login Contact Us Search LANGUAGE LANGUAGE ABOUT US Heritage Leadership Case Studies Cold Chain 101 Innovation & Technology Sustainability Inclusive Culture Foundation for Good SERVICES Global Warehousing Cold Storage Warehousing Port-Centric Warehousing Automated Warehousing Built-to-Suit Warehousing Fresh & Perishable Solutions Sustainable Warehousing Food Processing & Manufacturing Supply Chain Engineering Global Integrated Solutions Mana
TM Capital. Success. Realized. | NOVA Coldstore has been Acquired by Lineage Skip to content Who We Are Our Expertise Our Transactions Get In Touch Search Search for: Search All Transaction Details Previous Next Business Services | Mergers & Acquisitions, Sponsor Related NOVA Coldstore has been Acquired by Lineage TM Capital served as exclusive financial advisor to NOVA Coldstore Corp (“NOVA” or “The Company”) in connection with its sale to Lineage, a portfolio company of Bay Grove NOVA is a leading cold chain logistics provider that offers a comprehensive range of cold storage and related
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
Lineage Cell Therapeutics Appoints Jill Howe as CFO | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
XBRL Viewer Please enable JavaScript to use the EDGAR Inline XBRL Viewer.
Daily News Wrap up: Lineage Announces Acquisition of Bellingham Cold Storage LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agre … f start-ups and corporates in the biotech business Climate tech venture capital fund, Icos Capital, held the “Accelerating Sustainability Summit” at Bühler CUBIC Innovation Campus on March 28, 2025. The event brought together investors, industry leaders, and start-ups from the biotech sector to accelerate sustainable solutions, harnessing the power of Artificial Intelligence (AI).... Read More. How DBRC & Tetra Pak are improving the lives of waste pickers in Tirupati Wast … Jun 23, 2026 Daily News Wrap up: SIG and Seoul Dairy Win World Dairy Innovation Award for Alu-Free Aseptic Carton Packaging SIG and Seoul Dairy Win World Dairy Innovation Award for Alu-Free Aseptic Carton Packaging SIG and Seoul Dairy… 1 Jun 22, 2026 Daily News Wrap up: APEDA Facilitates First-Ever Export of Dried Whole Egg Powder from Odisha to Austria APEDA Facilitates First-Ever Export of Dried Whole Egg Powder from Odisha to Austria The Agricultural and Processed… Jun 19,
Immunomic Therapeutics Announces License Agreement With Lineage Cell Therapeutics for Cancer Immunotherapy - Immunomic Therapeutics Search for: Pipeline Partnerships Clinical Trials ITI-1000: Glioblastoma Multiforme ITI-1001: Glioblastoma Multiforme ITI-3000: Merkel Cell Carcinoma Team Careers Media Contact Us Pipeline Partnerships Clinical Trials ITI-1000: Glioblastoma Multiforme ITI-1001: Glioblastoma Multiforme ITI-3000: Merkel Cell Carcinoma Team Careers Media Contact Us Immunomic Therapeutics Announces License Agreement With Lineage Cell Therapeutics for Cancer Immunotherapy April 20, 202 … 77M by HLB Co., LTD, a global pharmaceutical company, enabled ITI to accelerate application of its immuno-oncology platform, in particular to glioblastoma multiforme, and rapidly advance other key candidates in the pipeline, including the most recent initiative into infectious diseases with development of its vaccine candidate for COVID-19. The Company has built a large pipeline from UNITE with eight oncology programs, multiple animal health programs and a SARS-CoV-2 program
Client Challenge JavaScript is disabled in your browser. Please enable JavaScript to proceed. A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.
Lineage | Acquisition Expands US Cold Storage Network Skip to Main Navigation Skip to Main Content Skip to Footer Links Team Resources Customer Login Lineage Link® Contact Us Search Language Search Language Lineage ABOUT US Heritage Leadership Case Studies Foundation for Good Cold Chain 101 Innovation & Technology Sustainability Inclusive Culture Lineage Ventures SERVICES Global Warehousing Cold Storage Warehousing Port-Centric Warehousing Automated Warehousing Built-to-Suit Warehousing Sustainable Warehousing Fresh & Perishable Solutions Food Processing & Manufacturing Supply Chai
Lineage (company) - Wikipedia Jump to content Main menu Main menu move to sidebar hide Navigation Main page Contents Current events Random article About Wikipedia Contact us Contribute Help Learn to edit Community portal Recent changes Upload file Special pages Search Search Appearance Donate Create account Log in Personal tools Donate Create account Log in Contents move to sidebar hide (Top) 1 History 2 Operations and technology 3 Acquisitions and expansion 4 Lineage Foundation for Good 5 Facilities 6 References 7 External links Toggle the table of contents Lineage (company) 2 languages Deuts … Good during its first year as a public charity. The same year, Lineage Hardship Fund launched to provide assistance to team members impacted by hardships, providing over $622,000 in 2022 to support 152 team members and their families through the Lineage Foundation for Good. [ 56 ] The Foundation has partnered with organizations including Feeding America and Global FoodBanking Network to help provide meals to those in need. [ 55 ] In 2023, Lineage and the Found … etrieved 2024-02-28 . ^ "Lineage Logistics Raises $1.9 Billion in New Equity to Fund Investment in Global Network Capacity and Industry-Leading Technology" . Yahoo! . March 11, 2021 . Retrieved 12 September 2021 . ^ de León, Riley. "Joe Lonsdale's 8VC partners with Lineage Logistics to double down on transportation and warehousing investments" . CNBC . Retrieved 15 September 2021 . ^ "Lineage Expands its European Footprint with New State-Of-The-Art Facility in France" . www.b … the Creative Commons Attribution-ShareAlike 4.0 License ; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy . Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc. , a non-profit organization. Privacy policy About Wikipedia Disclaimers Contact Wikipedia Legal & safety contacts Code of Conduct Developers Statistics Cookie statement Mobile view Search Search Toggle the table of contents Lineage (company) 2 lan
Mycobacterium tuberculosis Lineage Distribution Using Whole-Genome Sequencing and Bedaquiline, Clofazimine, and Linezolid Phenotypic Profiles among Rifampicin-Resistant Isolates from West Java, Indonesia Mycobacterium tuberculosis Lineage Distribution Using Whole-Genome Sequencing and Bedaquiline, Clofazimine, and Linezolid Phenotypic Profiles among Rifampicin-Resistant Isolates from West Java, Indonesia Int J Microbiol . 2024 Mar 4:2024:2037961. doi: 10.1155/2024/2037961. eCollection 2024. Authors Andriansjah Rukmana 1 , Cynthia Gozali 2 , Linda Erlina 3 Affil
Lineage | Five supply chain problems solved with Team Lineage Skip to Main Navigation Skip to Main Content Skip to Footer Links Team Resources Customer Login Contact Us Search LANGUAGE LANGUAGE ABOUT US Heritage Leadership Case Studies Cold Chain 101 Innovation & Technology Sustainability Inclusive Culture Foundation for Good SERVICES Global Warehousing Cold Storage Warehousing Port-Centric Warehousing Automated Warehousing Built-to-Suit Warehousing Fresh & Perishable Solutions Sustainable Warehousing Food Processing & Manufacturing Supply Chain Engineering Global Integrated Soluti … nsistent and customers saw no delays. Read the full case study 3. When a tariff deadline created a race against time Earlier in the year, a Canadian frozen food manufacturer was watching news about potential import tariffs. They understood what a sudden rule change could mean for the cost, availability and pricing of their product in the U.S. To stay ahead, they needed a cross-border plan and they needed it now. That meant identifying a U.S. cold storage facility close to the … rdinated the cross-border traffic and set up systems quickly enough to beat the deadline. That rapid alignment kept the supply chain intact: Freight crossed the border before any tariff impacts Frozen inventory remained available for U.S. retailers No added costs passed down the chain It’s a reminder that policy-driven disruptions often reward speed and flexibility. Read the full case study 4. When a port strike stalled nearly 50 refrigerated containers Labor disruptions don’
Board of Directors - Lineage Cell Therapeutics Company About Us Leadership Board of Directors Careers Contact Pipeline Overview OpRegen ® (Dry AMD) OPC1 (Spinal Cord Injury) Other Programs Technology AlloSCOPE TM Platform Manufacturing Media Investors News Events & Presentations Corporate Governance Charters and Documents Leadership Board of Directors Committee Composition Analyst Coverage Stock Information Stock Quote & Chart Historical Price Lookup Financials & Filings SEC Filings Annual Report and Proxy Information 2018 AgeX Form 10 and Information Statement 2019 Form 8937 E- … D., M.B.A. is the Co-Founder and Managing Director of Kidron Capital, a venture fund focused on investments in advancing women’s health, a position she has held since January 2022. She is also the Co-Founder and Managing Director of EXXclaim Capital, a venture fund also focused on innovation in women’s health, a position she has held since July 2017. In 2006, she co-founded the Evolvence India Life Science Fund, managing the fund until July of 2017. From 2001 to 2002, Dr. Jay
Lineage Takes Delivery of Genetically Engineered iPSC Line with Hypoimmunity Edits from Factor Bioscience | BioInformant BioInformant Your Global Leader in Stem Cell Market Research MENU MENU Blog News Stem Cells iPS Cells MSCs Exosomes Cord Blood HSCs Neural Stem Cells CAR-T Cells Interviews Shop Products About Submit Your News (PR) Advertise Testimonials Story Guarantee Contact $ 0 Home Blog Stem Cells HSCs iPS Cells MSCs Neural Stem Cells Adipose SCs Exosomes Cell Therapy CAR-T Cord Blood Stem Cell News Interviews COVID-19 Shop Submit PR Company Advertise Testimonials Story Job Posts Gu … ke on Twitter 2064467382437871985 View on Twitter 2064467382437871985 Load More Submit Press Release Advertise Privacy and Terms Copyright © 2026 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research | Email: [email protected] | Phone: 703-859-7617 | 800 Corporate Drive, Suite 301, Stafford, VA 22554, United States Disclaimer : All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose,
Lineage Cell Therapeutics... - Lineage Cell Therapeutics Facebook Log In Lineage Cell Therapeutics's Post Lineage Cell Therapeutics January 7 · Shared with Public Lineage Cell Therapeutics thanks Fierce Pharma's Fraiser Kansteiner for including CEO Brian Culley in a recent roundtable on what could shape #biopharma in 2026. Brian discussed why Lineage remains authentically optimistic, and why manufacturing matters, especially for complex, off-the-shelf cell therapies where CMC decisions can shape the path to scale and consistency. Read the full article: https://bit.ly/4jF2KjN #CellThe
Lineage Cell Therapeutics, Inc. (LCTX) 10-K Annual Report March 2025 HOME LOGIN PREMIUM SEC FILINGS FREE TRIAL API FOOTNOTED STOCK SCREENERS EARNINGS TRENDING INSIDER TRADING MANAGER PORTFOLIOS SENTIMENT ANALYSIS LATE NT SEC FILINGS Lineage Cell Therapeutics, Inc. (LCTX) SEC Filing 10-K Annual Report for the fiscal year ending Tuesday, December 31, 2024 Home SEC Filings Lineage Cell Therapeutics, Inc. (LCTX) 10-K Annual Report Mon Mar 10 2025 SEC Filings LCTX Valuations Intrinsic Value Financial Stability Financial Ratios Insider Trades Manager Portfolios Historical Financials (CSV) Not … r The liability-classified warrants issued in... Read more Revenue - Product We apply the revenue recognition... Read more Revenue - Product Royalties are payable to licensors... Read more Other - Other The amounts and timing of... Read more Other - Other It is currently not possible... Read more Other - Other ASC 740 guidance also prescribes... Read more Other - Other Our financial obligations primarily consist... Read more Revenue - Product We consider the terms of... Read … Other - Other If the assets are impaired,... Read more Other - Other We plan to apply for... Read more Financial - Expense These expenses consist of costs... Read more Financial - Expense Research and development costs with... Read more Revenue - Product Business—Grants from Government Entities,” above,... Read more Other - Other Our programs are based on... Read more Revenue - Product All of our manufacturing processes,... Read more Revenue - Product We have historically fun
Lineage | Global Cold Storage Warehousing & Integrated Solutions Skip to Main Navigation Skip to Main Content Skip to Footer Links Team Resources Customer Login Lineage Link® Contact Us Search Language Search Language Lineage ABOUT US Heritage Leadership Case Studies Foundation for Good Cold Chain 101 Innovation & Technology Sustainability Inclusive Culture Lineage Ventures SERVICES Global Warehousing Cold Storage Warehousing Port-Centric Warehousing Automated Warehousing Built-to-Suit Warehousing Sustainable Warehousing Fresh & Perishable Solutions Food Processing & Manufactur
LCTX CEO buys 15,000 shares in open market | LCTX Insider Trading --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI Stocks Crypto Stocks Oil & Ga
%PDF-1.7 %������� 1 0 obj [/PDF/ImageB/ImageC/ImageI/Text] endobj 2 0 obj > endobj 4 0 obj >stream x�3T0B]C ani���� I\ endstream endobj 5 0 obj 23 endobj 6 0 obj > endobj 7 0 obj > endobj 8 0 obj [/Indexed/DeviceRGB 127 9 0 R] endobj 9 0 obj >stream x�c``�������� ݿ7l�{�ʿ ?1�P��`�����Cව� �?'���`���>x�����o�=y����;7nܜ8iJGgwCc��y f͞��W���������������+V^�t���SG� ����{�m߱q����dL �_:���1���(��8��M�^[0}[����k��?z���g�_�� z��x�� ҁn endstream endobj 10 0 obj >stream x�� o�:�e��\�Q��UTU�\�`���_�Wb;a�f۷R�8cǙ�s�� ��Z���n>+�� ��5��$I�++ �a�w]� ���a�ե1� qd'q��I �06�M#b��E(�HYd3
Lineage | Acquires Luik Natie in Belgium Skip to Main Navigation Skip to Main Content Skip to Footer Links Team Resources Customer Login Lineage Link® Contact Us Search Language Search Language Lineage ABOUT US Heritage Leadership Case Studies Foundation for Good Cold Chain 101 Innovation & Technology Sustainability Inclusive Culture Lineage Ventures SERVICES Global Warehousing Cold Storage Warehousing Port-Centric Warehousing Automated Warehousing Built-to-Suit Warehousing Sustainable Warehousing Fresh & Perishable Solutions Food Processing & Manufacturing Supply Chain Engineering
Lineage Cell plans 2026 shareholder votes on board, pay | LCTX Proxy Statement --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI Stocks Crypto St … do not need to attend the Meeting to vote your shares. Instead, you may simply submit your proxy in accordance with the instructions provided on the Notice of Internet Availability of Proxy Materials, or if you elected to receive printed copies of the proxy materials, you may submit your proxy by completing, signing and returning the enclosed proxy card. See also, “How do I vote?” below. The proxy materials were first sent or made available to our shareholders on … voting on? These are the proposals scheduled for a vote at the Meeting: • Proposal 1: To elect seven directors to hold office until the 2027 annual meeting of shareholders and until their respective successors are duly elected and qualified. • Proposal 2: To ratify the appointment of Baker Tilly US, LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2026. • Proposal 3: To approve, on an advisory basis, the compen … your common shares, you may revoke your proxy in any one of four ways: • submit another properly completed proxy card with a later date; • vote again by Internet or telephone at a later time (only the latest Internet or telephone proxy submitted prior to the Meeting will be counted); • send a written notice to us at 2173 Salk Avenue, Suite 200, Carlsbad, CA 92008; Attention: Corporate Secretary; or • attend the Meeting and vote in person (attending th … te how you want to vote your common shares for a particular director nominee or proposal or for all the director nominees and proposals, then as to each nominee and proposal for which you do not so indicate your voting choice, your shares will be voted in accordance with our Board’s recommendation. Beneficial Owner: Common Shares Registered
Informatica Network Loading × Sorry to interrupt CSS Error Refresh
Cell therapy has been “the future of medicine” for 30 years…so why hasn’t it scaled (yet)? In our latest episode of Progress, Potential, And Possibilities I sat down with Brian Culley, CEO of Lineage Cell Therapeutics to unpack one of the hardest problems in biotech: 👉 How do you manufacture living cells at scale? For decades, the vision has been clear - replace damaged cells in diseases like macular degeneration, spinal cord injury, hearing loss, and Type 1 diabetes. But the reality? It’s not just a biology problem - it’s a manufacturing, engineering, and cost problem. Brian brings 30+ years
Lineage Logistics acquires VersaCold Logistics… | TorQuest Partners Strategy Team Investments Responsible Investing Scholars Program News Contact Us en fr August 3, 2022 Lineage Logistics acquires VersaCold Logistics Services from TorQuest NOVI, Mich. — Lineage Logistics, LLC (“Lineage” or the “ Company”), one of the world’s leading and most innovative temperature-controlled industrial REITs and logistics solutions providers, today announced it has closed the acquisition of VersaCold Logistics Services (“VersaCold”). VersaCold is a leading cold chain solution provider in Canada tha … bsp;investors. VersaCold was the first platform investment by TorQuest Partners Fund V, a $1.375 billion fund that closed in March 2020. The acquisition was first announced on April 13, 2022. VersaCold is a leading cold chain solution provider in Canada that operates 24 temperature-controlled facilities spanning 114 million cubic feet of capacity across nine provinces. Its strategically-positioned network includes properties in Canada’s most populous metropolit
%PDF-1.6 %���� 799 0 obj > endobj 816 0 obj >/Filter/FlateDecode/ID[ ]/Index[799 30]/Info 798 0 R/Length 92/Prev 3696951/Root 800 0 R/Size 829/Type/XRef/W[1 3 1]>>stream h�bbd```b``�� � �� �dy"�O�I!ɴ�> &g�E��l�fW�g&�d���$�O�������,��H&���ߵog�7 endstream endobj startxref 0 %%EOF 828 0 obj >stream h��Uqle�����f*Ybn��V�lu�a�Ip% �0l��lR�EW�b�,�D\�����֠H���-�r%X��HV�?KH�I��AT�1$��n�vſ��K����~����ޗ�BL�@ YA5L�I�)Gf%ⴂ[���3�l V"��Z���'>�6�6�%qb��큻>_���c��h�'� �ߍR�{�3���v{�L�/���~:���h� �ݻ*KRT�5��9[��ቦ�;�9�vǗ�O�t�mW�pU�&kޥ�返�+��A�B���K� ��w_�o����p&΄��×^���\��� … h�277S0P077W02P����+�-��(���ł�]�� �� z endstream endobj 564 0 obj >stream application/pdf rr829295 Sanitized.pdf PScript5.dll Version 5.2.2 2026-04-27T15:50:21-07:00 2026-04-27T15:50:21-07:00 Acrobat Distiller 26.0 (Windows) uuid:7d3b5d0e-8033-4d20-a388-4af21913302d uuid:2d578e9d-fa1e-4d86-bbd5-29b78f50438f endstream endobj 565 0 obj >stream hޜ��n1E�0��]m)ʆ%�(b�XDb��"��ﱧN)����U���)߲�[�%b�[-6U�n}��2�J���� �Z�>?3f�9�TY/�"r�Et�̟�V̐">�bh��� �4_o���כVd\bzQ��DQ�1
Eterna Therapeutics Enters Into Option and License Agreement With Lineage Cell Therapeutics to Develop Hypoimmune Pluripotent Cell Lines for Multiple Neurology Indications - Factor Bioscience Science Technology Presentations and Publications Patents Pipeline Partners About News Contact Eterna Therapeutics Enters Into Option and License Agreement With Lineage Cell Therapeutics to Develop Hypoimmune Pluripotent Cell Lines for Multiple Neurology Indications February 22, 2023 CAMBRIDGE, MASS. – February 22, 2023 – Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna”), … any products on a timely basis or at all; (iv) Eterna’s ability to successfully fund and manage the growth of its development activities; (v) Eterna ’s ability to obtain regulatory approvals of its products for commercialization; and (vi) uncertainties related to the impact of the COVID-19 pandemic on the business and financial condition of Eterna, including on the timing and cost of its clinical trials. You should not rely upon forward-looking statements as predictions of fu … Scientist Job Type: Full-Time Job Duration: Indefinite Min Education: Master’s Apply for this job First name * Last name * Email * Phone * Do you currently reside within the Continental United States or Canada? Select... Yes No How active are you in your job search? Are you able to work in the Boston area or are you willing to relocate for this position? Select... Yes No What about this role inspired you to apply? When would you be able to start a new position? Resume Upload … 5MB Cover Letter Upload a file or drag and drop. pdf, rtf, doc, docx up to 5MB Submit application Franklin Kostas Associate Scientist Realizing Achievement and Direction through His Research Franklin Kostas joined one of Factor Bioscience’s spinoffs, Novellus Therapeutics, as an Associate Scientist after graduating with a Bachelor of Science degree in chemistry from Haverford College in 2018. Many from his graduating class went straight into graduate school or took technicia … lly will increase their efforts,” he said. “That’s something that I’ve tried to apply to other parts of my life.” A Discovery at the Interface of Chemistry and Biology Franklin designed and executed many rounds of experiments using both panels of lipid and polymer-based reagents that he selected for this purpose as well as molecules that he desig
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
Lineage | Telegraph Partnership Skip to Main Navigation Skip to Main Content Skip to Footer Links Team Resources Customer Login Lineage Link® Contact Us Search Language Search Language Lineage ABOUT US Heritage Leadership Case Studies Foundation for Good Cold Chain 101 Innovation & Technology Sustainability Inclusive Culture Lineage Ventures SERVICES Global Warehousing Cold Storage Warehousing Port-Centric Warehousing Automated Warehousing Built-to-Suit Warehousing Sustainable Warehousing Fresh & Perishable Solutions Food Processing & Manufacturing Supply Chain Engineering Global I
Facebook Explore the things you love . Log into Facebook Email or mobile number Password Log in Forgot password? Create new account English (US) فارسی العربية Türkçe Deutsch Français (France) Polski More languages… Sign Up Log In Messenger Facebook Lite Video Meta Pay Meta Store Meta Quest Ray-Ban Meta Meta AI Instagram Threads Privacy Policy Privacy Center About Create ad Create Page Developers Careers Cookies Ad choices Terms Help Contact Uploading & Non-Users Meta © 2026
Lineage, Inc. (Form: 8-K, Received: 07/26/2024 16:35:50) false 0001868159 --12-31 0001868159 2024-07-24 2024-07-24     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2024     Lineage, Inc. (Exact name of registrant as specified in its charter)       Maryland   001-42191   82-1271188 (State or other jurisdiction of incorporation)   … Mr. Turner and Ms. Wentworth will serve on the Company’s Equity Award Committee. Messrs. Forste, Marchetti and Turner and Mses. Archambeau, Falotico and Wentworth were nominated by BGLH, Messrs. Taylor and Wyper were nominated by Stonepeak and Mr. Carrafiell was nominated by BGO, in each case, pursuant to the Stockholders Agreement and elected to the Board of Directors of the Company. Biographical information regarding the directors, equity awards made to … cept that the representations and warranties set forth in this paragraph do not apply to statements or omissions in the Registration Statement, the Time of Sale Prospectus or the Prospectus based upon information relating to any Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for use therein. 3 (c) The Company is not an “ineligible issuer” in connection with the offering pursuant to Rules 164, 4 … ries is, and after giving effect to the offering and sale of the Shares and the application of the proceeds thereof as described in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus, none of the Transaction Entities will be, required to register as an “investment company” or an entity “controlled” by an “investment company” as such terms are defined in the Investment Company Act of 1940, as amended. … to any subsidiary, joint venture partner or other Person: (A) to fund or facilitate any activities or business of or with any Person or in any country or territory that, at the time of such funding or facilitation, is, or whose government is, the subject of Sanctions; or (B) to fund or facilitate any money laundering
Lineage CEO to Share Novel Eye Drug Delivery Advances at AAO Conference | LCTX Stock News --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI Stock
Raven.config('https://[email protected]/147999').install(); Lineage to Present at 2024 BIO International Convention | INN Connect with us Information About Us Contact Us Careers Partnerships Advertise With Us Authors Browse Topics Events Disclaimer Privacy Policy Australia North America World Login Investing News Network Your trusted source for investing success North America Australia World My INN Videos Companies Press Releases Private Placements SUBSCRIBE Reports & Guides Market Outlook Reports Investing Guides Button Resource Precious Metals Battery Metals Base … esting MAYFAIR ANNOUNCES RESULTS OF 2026 ANNUAL GENERAL AND SPECIAL MEETING AND GRANT OF STOCK OPTIONS 21h base metals investing Great Western Mining Corporation PLC Announces Result of AGM 25 June TOP STOCKS American Battery 4.03 0.24 Aion Therapeutic 0.10 -0.01 Cybin Corp 2.14 0.00
Careers - Lineage Cell Therapeutics Company About Us Leadership Board of Directors Careers Contact Pipeline Overview OpRegen ® (Dry AMD) OPC1 (Spinal Cord Injury) Other Programs Technology AlloSCOPE TM Platform Manufacturing Media Investors News Events & Presentations Corporate Governance Charters and Documents Leadership Board of Directors Committee Composition Analyst Coverage Stock Information Stock Quote & Chart Historical Price Lookup Financials & Filings SEC Filings Annual Report and Proxy Information 2018 AgeX Form 10 and Information Statement 2019 Form 8937 E-mail Alerts … ackage. If you are interested in applying for any of our open positions, please submit your resume to [email protected] . Currently Available Positions (click on a job listing below to read more) Currently, there are no available positions. Please check back soon. Director of Clinical Operations Lineage is seeking a Director of Clinical Operations to join our team. This position is full-time, reporting to the SVP, Head of Clinical. The role requires on-site presence and … opment of in-house operations, SOPs, guidelines, work instructions and systems. Submit protocols to IRB/EC, assist clinical testing laboratories with IRB/EC submissions, and ensure collection and review of required essential study documents and reports. Oversee and support relevant DSMB functions. Ensure that clinical study conduct and record management (e.g. Trial Master Files) are in adherence to global regulations and guidelines, company quality standards and standard oper
Careers - Lineage Cell Therapeutics Company About Us Leadership Board of Directors Careers Contact Pipeline Overview OpRegen ® (Dry AMD) OPC1 (Spinal Cord Injury) Other Programs Technology AlloSCOPE TM Platform Manufacturing Media Investors News Events & Presentations Corporate Governance Charters and Documents Leadership Board of Directors Committee Composition Analyst Coverage Stock Information Stock Quote & Chart Historical Price Lookup Financials & Filings SEC Filings Annual Report and Proxy Information 2018 AgeX Form 10 and Information Statement 2019 Form 8937 E-mail Alerts … ackage. If you are interested in applying for any of our open positions, please submit your resume to [email protected] . Currently Available Positions (click on a job listing below to read more) Currently, there are no available positions. Please check back soon. Director of Clinical Operations Lineage is seeking a Director of Clinical Operations to join our team. This position is full-time, reporting to the SVP, Head of Clinical. The role requires on-site presence and … opment of in-house operations, SOPs, guidelines, work instructions and systems. Submit protocols to IRB/EC, assist clinical testing laboratories with IRB/EC submissions, and ensure collection and review of required essential study documents and reports. Oversee and support relevant DSMB functions. Ensure that clinical study conduct and record management (e.g. Trial Master Files) are in adherence to global regulations and guidelines, company quality standards and standard oper
Lineage Cell Therapeutics earns $5M Roche milestone payment | LCTX 8-K Filing --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI Stocks Crypto Sto
XBRL Viewer Please enable JavaScript to use the EDGAR Inline XBRL Viewer.
Exhibitor Lists | Seafood Expo North America March 7-9, 2027 | Boston, USA Attend Why Attend? Visit Seafood Processing North America Key Buyer Program Seafood Processing & Aquaculture Buyer Program FAQs Attendee Inquiry Visa Invitation Letters Exhibit Why Exhibit? New Product Showcase Featured Product Showcase Seafood Processing North America Floor Plan Official Vendors Exhibitor FAQs Exhibitor Inquiry Exhibitor List Exhibitor List Floor Plan Conference Call for Proposals Conference Information Conference Program Speakers Call for Proposals Opt-In Form Event Highlights Onsite Experiences E … case (Product Page) Featured Product Showcase (Product Page) Seafood Excellence Award Winners Oyster Shucking Competition Hotel/Travel Hotel Shuttle Schedule and Routes About Seafood Expo North America Supporting Partners Official Media Official Vendors Press Center Contact Information FAQs Attend Why Attend? Visit Seafood Processing North America Key Buyer Program Seafood Processing & Aquaculture Buyer Program FAQs Attendee Inquiry Visa Invitation Letters Exhibit Why Exh … case (Product Page) Featured Product Showcase (Product Page) Seafood Excellence Award Winners Oyster Shucking Competition Hotel/Travel Hotel Shuttle Schedule and Routes About Seafood Expo North America Supporting Partners Official Media Official Vendors Press Center Contact Information FAQs Search Learn More 2026 Exhibitor List Who will be at Seafood Expo North America/Seafood Processing North America? View a list of exhibitors from the 2025 edition of Seafood Expo North Amer
Henrique Faria | CONDUCTOR Exhibitor Skip to main content events Calendar The Ark events fabrication Ceramics Projects at any scale, guided and executed by expert fabricators Print Printmaking with a focus on innovation and experimentation Public Art Support and expertise from concept and design through fabrication and installation The Alpha Workshops Handmade wallpapers and textiles + decorative arts training Featured Projects A portfolio of work fabricated at PHA Artist Subsidy Program Subsidizing fabrication services for New York City–based artists facing financial barriers Artist-in-Reside … YCO PROXYCO Light for the Amazon Peru Light for the Amazon Light for the Amazon Residency Unlimited Brooklyn, NY Residency Unlimited Residency Unlimited EXTRA Galería Guatemala City, Guatemala EXTRA Galería EXTRA Galería Brihatta Art Foundation Dhaka, Bangladesh Brihatta Art Foundation Brihatta Art Foundation RAQUEL PATER São Paulo, Brazil RAQUEL PATER RAQUEL PATER Previous Previous Next Next Footer 322 3rd Avenue Brooklyn, NY 11215 Lenapehoking 718.522.1400 Stay connected
Other Programs - Lineage Cell Therapeutics Company About Us Leadership Board of Directors Careers Contact Pipeline Overview OpRegen ® (Dry AMD) OPC1 (Spinal Cord Injury) Other Programs Technology AlloSCOPE TM Platform Manufacturing Media Investors News Events & Presentations Corporate Governance Charters and Documents Leadership Board of Directors Committee Composition Analyst Coverage Stock Information Stock Quote & Chart Historical Price Lookup Financials & Filings SEC Filings Annual Report and Proxy Information 2018 AgeX Form 10 and Information Statement 2019 Form 8937 E-mail … reclinical development of ReSonance for the treatment of hearing loss. WDI will fund up to $12 million in planned research collaboration costs over the approximate three-year term of the agreement. COR1 - Corneal Endothelial Cell (CEnC) Cell Therapy Program Corneal endothelial disease is a progressive, often hereditary condition where cells on the inner layer of the cornea die, causing cornea swelling and vision loss. Applicable indications for COR1 are expected to include Fu … r optimized process with our non hypoimmune line. Importantly, we expect we can apply insights and process improvements we have learned or will learn through this process to our other cell transplant programs, including programs we may launch in the future. RND1 - Hypoimmune Research Initiative RND1 is a novel hypoimmune iPSC cell line being evaluated in collaboration with our gene editing partner Factor Biosciences for the development of a cell transplant candidate for the p
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
Lineage, Language & Landscape: Poetry Debuts – Poetry - Miami Book Fair Skip to content X-twitter Facebook Instagram Youtube Linkedin Login English English Spanish Haitian Creole Donate Search Programs Upcoming Events On Demand The Fair Miami Book Fair Overview Street Fair Sponsors Exhibitor Application Directions & Parking Fair Guide Exhibitors The Next Page Employment Opportunities Author Program Submission Guidelines Authors Become a Friend Programs Upcoming Events On Demand The Fair Miami Book Fair Overview Street Fair Sponsors Exhibitor Application Directions & Parking Fair … iza: Poems (University Press of Kentucky) and the chapbook Alien(s). A Pushcart Prize winner, she has been featured by Poets & Writers and in Ms. magazine, the Association of Writers & Writing Programs’ The Writer’s Chronicle, and HipLatina, among others. She teaches creative writing in Southern California, where she lives with her family and pets. You can find her online at YaelAldana.com and @yaelwrites. Thank you to our Partners Recommended events November 23, 20
Lineage Collections - High Point Market {s.remove();});"> Skip to navigation Skip to main content Skip to footer Register | Oct 17-21, 2026 Oct 17-21, 2026 Exhibitor Services Sponsors & Partners MediaLink Exhibitor Directory Inspiration Inspiration Discover a wealth of creative inspiration, unique trends and style forecasts at High Point Market. Products + New Product Picks Product + Showroom News Trends + Future Snoops Style Spotters Register Plan Your Trip Plan Your Trip We’ve made it easy to make all of your travel arrangements from booking accommodations in advance to navigating Market aft
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
Brian Culley - #SCIsymposium | Lineage Cell Therapeutics LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privacy Poli
Lineage Cell Therapeutics’ CEO Brian Culley appreciated the opportunity to participate in Mizuho America, Inc.’s 2025 Neuro & Ophthalmology Summit, in a keynote panel led by Graig Suvannavejh, PhD, Senior Analyst, US Healthcare. Read more: https://bit.ly/4kn8M7G #ReplaceandRestore | Lineage Cell Therapeutics
EXHIBITOR SHOWCASE Few companies... - Chicago Drum Show Facebook Log In Chicago Drum Show's Post Chicago Drum Show is at Chicago Drum Show . March 5 · Shared with Public EXHIBITOR SHOWCASE Few companies today have a lineage going back over 100 years and even fewer people started their career in the drum industry as a 3rd grader like our next exhibitor did. For over sixty years Bill Ludwig III has dedicated his life to the success of drummers. He has worked with the biggest names in music history and knows what drummers need and want. All of that experience and passion went into resurrecti
Lineage Cell Therapeutics | Biotech Careers Skip to main content Biotech Careers Contact Submit an Employer Contact Add an Employer Search Open main menu Contact Submit an Employer Contact Add an Employer Search Main navigation Careers Job Areas People Articles Videos Biotech Companies Biotech Jobs Business Areas Lineage Cell Therapeutics Website: Lineage Cell Therapeutics Business Area(s) Cell and Gene Therapy Eye care Spinal Health Cancer Therapeutics Description Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Linea
Dendritic cells(Lineage Cell Therapeutics, Inc.) - Drug Targets, Indications, Patents - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 04 Apr 2026 Dendritic cells(Lineage Cell Therapeutics, Inc.) Last update 04 Apr 2026 Overview R&D Status Clinical Result Translational Medicine Deal Core Patent Clinical Trial Approval Regulation Overview Basic Info Drug Type Therapeutic vaccine, Dendritic cell vaccine Synonyms AST-VAC 2, GRNVAC 2, VAC 2 + [1] Target TERT Action inhibitors Mechanism TERT inhibitors(Telomerase reverse transcriptase inhibitors) Therapeutic Areas … s. We are excited to see these initial VAC2 clinical data from a first-in-human application in what is the most common form of lung cancer and are hopeful that we can continue our collaborative work with Lineage on the next phase of development for this promising treatment approach,” added Nigel Blackburn, PhD, Cancer Research UK’s Director of Drug Development. On May 7th, 2020, Lineage completed an early exercise of its option to acquire data from Cancer Research UK and assu … s intend to present these data at future medical and scientific conferences and submit publications to relevant journals for peer review. About Lineage Cell Therapeutics, Inc. Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage's programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage d … traZeneca and Daiichi Sankyo reported that their supplemental Biologics License Application (sBLA) for Enhertu was granted Priority Review by the U.S. Food and Drug Administration. AstraZeneca and Daiichi Sankyo reported that their supplemental Biologics License Application (sBLA) for Enhertu (trastuzumab deruxtecan) was granted Priority Review by the U.S. Food and Drug Administration . The sBLA is for adults with unresectable or metastatic non-small cell lung cancer (NSCLC)
Dendritic cells(Lineage Cell Therapeutics, Inc.) - Drug Targets, Indications, Patents - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 04 Apr 2026 Dendritic cells(Lineage Cell Therapeutics, Inc.) Last update 04 Apr 2026 Overview R&D Status Clinical Result Translational Medicine Deal Core Patent Clinical Trial Approval Regulation Overview Basic Info Drug Type Therapeutic vaccine, Dendritic cell vaccine Synonyms AST-VAC 2, GRNVAC 2, VAC 2 + [1] Target TERT Action inhibitors Mechanism TERT inhibitors(Telomerase reverse transcriptase inhibitors) Therapeutic Areas … s. We are excited to see these initial VAC2 clinical data from a first-in-human application in what is the most common form of lung cancer and are hopeful that we can continue our collaborative work with Lineage on the next phase of development for this promising treatment approach,” added Nigel Blackburn, PhD, Cancer Research UK’s Director of Drug Development. On May 7th, 2020, Lineage completed an early exercise of its option to acquire data from Cancer Research UK and assu … s intend to present these data at future medical and scientific conferences and submit publications to relevant journals for peer review. About Lineage Cell Therapeutics, Inc. Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage's programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage d … traZeneca and Daiichi Sankyo reported that their supplemental Biologics License Application (sBLA) for Enhertu was granted Priority Review by the U.S. Food and Drug Administration. AstraZeneca and Daiichi Sankyo reported that their supplemental Biologics License Application (sBLA) for Enhertu (trastuzumab deruxtecan) was granted Priority Review by the U.S. Food and Drug Administration . The sBLA is for adults with unresectable or metastatic non-small cell lung cancer (NSCLC)
Lineage Cell Therapeutics, Inc. Ownership Profile and Analysis -- Fintuitive Loading... You are using an outdated browser. Please upgrade your browser to improve your experience and security. Settings Logout Dashboard Investment Managers Crowded Trades Conviction Trades Manager Stock Flows Manager Filters Mutual Funds / ETFs Fund Stock Flows Fund Filters Lineage Cell Therapeutics, Inc. (LCTX) 2173 SALK AVENUE, SUITE 200, CARLSBAD, CA, 92008 Geographical Distribution Showing data for Mar 2026 Dec 2025 Sep 2025 Jun 2025 Mar 2025 Dec 2024 Sep 2024 Jun 2024 Mar 2024 Dec 2023 Sep 2023 Jun 2023 Mar … ys Top Sells Top Institutional Owners History Prior Institutional Owners Mutual Fund/ETF Owners Mutual Fund/ETF Short Owners --> Showing data for Q1-2026 Q4-2025 Q3-2025 Q2-2025 Q1-2025 Q4-2024 Q3-2024 Q2-2024 Q1-2024 Q4-2023 Q3-2023 Q2-2023 Q1-2023 Q4-2022 Q3-2022 Q2-2022 Q1-2022 Q4-2021 Q3-2021 Q2-2021 Q1-2021 Q4-2020 Q3-2020 Q2-2020 Q1-2020 Q4-2019 Q3-2019 Q2-2019 Q1-2019 Q4-2018 Q3-2018 Q2-2018 Q1-2018 Q4-2017 Q3-2017 Q2-2017 Q1-2017 Q4-2016 Q3-2016 Q2-2016 Q1-2016 Q4-201 … Q3-2015 Q2-2015 Q1-2015 Q4-2014 Q3-2014 Q2-2014 Q1-2014 Q4-2013 Q3-2013 Q2-2013 Fund Title of Class Value ($mm) Actions Rank Name Options Total Shares O/S (%) Dollar Value ($mm) Current Dollar Value ($mm) Previously Owned Position Initiated Period Quality Value Small Size Volatility Momentum Dividend Revenue Growth (YoY) Revenue Growth (3 Yrs) Portfolio % Portfolio Position Fund Size ($mm) Change Est. Cost Basis Est. Gain / Loss % Qtr End Gain / Loss % Investor Type Classific … tfolio Percentage Portfolio Position Est. Cost Basis Est. Gain / Loss % Actions Fund Name Previous. Num. Shares Difference Num. Shares Previous Dollar Value ($mm) Dollar Value Difference ($mm) Current Dollar Value ($mm) Position Initiated Est. Cost Basis Est. Gain / Loss Actions ** - Stocks bought during IPO Fund Name Previous. Num. Shares Difference Num. Shares Previous Dollar Value ($mm) Dollar Value Difference ($mm) Current Dollar Value$($mm) Position Initiated Actions Ran … ifference ($mm) Current Dollar Value$($mm) Position Initiated Actions Rank Name Fund Types Index Fund Fund Ticker Advisors Reporting Period Portfolio Percentage Company Percentage Number of Shares Value ($ mn) Classification Net Assets ($ mn) Quality Value Small Size Volatility Momentum Dividend Revenue Growth (YoY) Revenue Growth (3 Yrs) Actions
Lineage Cell Therapeutics, Inc. (NYSE MKT: LCTX) :: LD Micro Special Announcement: LD Main Event XX: Tournament of Champions is in 115 Days Register HERE » Home Home Events LD Micro Main Event XX About LD Micro Contact LD Micro Index: The Benchmark In Microcap Breaking .slide" data-cycle-swipe="true" data-cycle-prev=".cycle-prev" data-cycle-next=".cycle-next" data-cycle-timeout="7000" data-cycle-auto-height=container data-cycle-log="false"> Vox Royalty Sells I-80 Gold Offtake Stream (1 of 3) Luna (LUNA) Enters into Definitive Agreement to be Acquired by TJC (2 of 3) Interlink (LINK) Sele
Thank you to Maxim Group LLC... - Lineage Cell Therapeutics Facebook Log In Lineage Cell Therapeutics's Post Lineage Cell Therapeutics October 23, 2025 · Shared with Public Thank you to Maxim Group LLC for hosting an insightful cell therapy panel yesterday at its 2025 Growth Summit. It was a great opportunity for Lineage Cell Therapeutics CEO Brian Culley to discuss the future of regenerative medicine. #ReplaceandRestore #InvestorRelations All reactions: 7 2 shares Like Comment
Raven.config('https://[email protected]/147999').install(); Lineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update | INN Connect with us Information About Us Contact Us Careers Partnerships Advertise With Us Authors Browse Topics Events Disclaimer Privacy Policy Australia North America World Login Investing News Network Your trusted source for investing success North America Australia World My INN Videos Companies Press Releases Private Placements SUBSCRIBE Reports & Guides Market Outlook Reports Investing Guides Button … xisting ophthalmology and manufacturing expertise and represents a natural next application of our platform. We also achieved our first milestone with our AlloSCOPE 5D manufacturing initiative, aimed at addressing the challenges of large scale production of undifferentiated pluripotent stem cells. If successful at a larger scale, the overall goal is to leverage this initiative, together with a differentiation protocol, to address the insufficient supply of islet cells needed … xisting ophthalmology and manufacturing expertise and represents a natural next application of our technology platform. Applicable indications for COR1 are expected to include Fuchs Endothelial Corneal Dystrophy (FECD) and Bullous Keratopathy. Utilizing Lineage's proprietary cell manufacturing and expansion platform, AlloSCOPE™ , the Company is manufacturing "off the shelf" corneal endothelial cells with identity, morphological, and functional characteristics wh … two final cell-based product candidates. AlloSCOPE "5D" describes an application of AlloSCOPE with the goal of higher scale production with reduced manipulation. About Lineage Cell Therapeutics, Inc . Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel allogeneic, or "off the shelf", cell therapies for serious medical conditions. Lineage's programs are based on its proprietary cell-based technology platform, AlloSCOPE™ … e applied across multiple programs; Lineage's plans to, and its ability to, apply its manufacturing capabilities to establish a production modality that, if successful, and if paired with an islet-cell differentiation protocol, could potentially address manufacturing scale considerations relevant to potential future islet cell therapy product
#bio2024 #celltherapy #biotech #replaceandrestore | Lineage Cell Therapeutics LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agr
On the ground at #BIO2024! Yesterday, our CEO Brian Culley presented an update on how Lineage Cell Therapeutics is advancing its diverse pipeline of novel cell therapies at BIO International Convention. #ReplaceandRestore | Lineage Cell Therapeutics
Lineage to Present at 2024 BIO International Convention - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Biotech Beach Lineage to Present at 2024 BIO International Convention May 30, 2024 | 3 min read Twitter LinkedIn Facebook Email Print Lineage Cell Therapeutics, Inc. today announced that the Company’s CEO, Brian M. Culley, will present at the 2024 BIO International Convention, on Tuesday June 4th, 2024, at 2:30pm in The … bsp; 2 min read · Tristan Manalac Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst China BIO 2026: US needs to dodge China’s ‘inescapable dependencies’ to protect biotech June 24, 2026 · 2 min read · Annalee Armstrong BioSpace at BIO to find out" href="https://www.biospace.com/drug-development/can-adcs-be-kin … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
Lineage Cell Therapeutics - Drug Discovery World (DDW) Drug Discovery World (DDW) About Us | Subscribe Free | Media Info | Contact Us | Log In News Exclusive Content Features Opinion Market Reports Trends & Analysis Start-up Zone DDW eBooks Business & Investment Regulatory Events DDII Events Series Other Events Webinars Resources Magazine Digital Issues Archive Multimedia Videos Podcasts Topic filter: Cancer Research Immunology / Virology & Vaccines Advanced Therapies Neuroscience Multiomics Artificial Intelligence Automation & Robotics Therapeutic Antibodies Microbiome Drug Discovery Cell
Lineage is a proud sponsor of the National Fisheries Institute 2026 Global Seafood Market Conference! If you’ll be in attendance, connect with our team to learn how Lineage’s global network and full… | Lineage LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any t
LCTX - Lineage Cell Therapeutics Inc Stock Price and Quote Home News Screener Charts Maps Groups Portfolio Insider Futures Forex Crypto Calendar Pricing Theme Help Login Register LCTX Lineage Cell Therapeutics Inc Last Close 1.28 Jun 26 • 04:00PM ET Dollar change +0.06 Percentage change (4.92%) Overview Compare Short Interest Financials Options Filings Latest Filings Healthcare Biotechnology USA Small AMEX Peers : EDIT RGNX BEAM NTLA CRSP BMRN INCY KRYS RYTM AXSM Scroll to Statements Index - P/E - EPS (ttm) -0.29 Insider Own 24.81% Shs Outstand 249.30M Perf Week 5.79% Market Cap 31 … Update on May 9, 2024 (Business Wire) -7.08% Apr-30-24 08:00AM Lineage Receives Grant From California Institute for Regenerative Medicine (CIRM) (Business Wire) Apr-29-24 04:30PM Lineage Announces Changes to Board of Directors (Business Wire) Apr-19-24 12:13PM 12 Cheap Foods With Anti-Aging Properties That Longevity Scientists Swear By (Insider Monkey) Apr-01-24 08:00AM Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development (Busi
0000876343 false FY 0000876343 2022-01-01 2022-12-31 0000876343 2022-06-30 0000876343 2023-03-03 0000876343 2022-12-31 0000876343 2021-12-31 0000876343 2021-01-01 2021-12-31 0000876343 us-gaap:PreferredStockMember 2020-12-31 0000876343 us-gaap:CommonStockMember 2020-12-31 0000876343 us-gaap:RetainedEarningsMember 2020-12-31 0000876343 us-gaap:NoncontrollingInterestMember 2020-12-31 0000876343 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0000876343 2020-12-31 0000876343 us-gaap:PreferredStockMember 2021-12-31 0000876343 us-gaap:CommonStockMember 2021-12-31 0000876343 us-gaap:Ret … eding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐   Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth comp … to satisfy specified conditions to manufacture products and transfer or license grant-supported technologies outside of Israel. In the context of such approvals, we will be required to pay penalties in addition to the repayment of the grants.         ● We have relied on grant funding from CIRM to support clinical development of OPC1 and we may not be able to obtain additional CIRM funding. In addition, our profits from the sale of products resulting … created by specific developmental biological differentiation protocols that we apply to established, well-characterized, and self-renewing pluripotent cell lines. These cells are transplanted into patients and are designed to (a) replace or support cells that are absent or dysfunctional due to degenerative disease, aging, or traumatic injury, and (b) restore or augment functional activity in the affected person.   Our strategy is to efficiently leverage our technology p … development of OPC1 has been partially funded by $14.3 million received under a grant from the California Institute for Regenerative Medicine (“CIRM”). Additional clinical trials are being planned.         ● VAC , an allogeneic cancer immunotherapy comprised of antigen-presenting dendritic cells. One of the V
Lineage | Lineage & 8VC to Transform Logistics Tech Skip to Main Navigation Skip to Main Content Skip to Footer Links Team Resources Customer Login Lineage Link® Contact Us Search Language Search Language Lineage ABOUT US Heritage Leadership Case Studies Foundation for Good Cold Chain 101 Innovation & Technology Sustainability Inclusive Culture Lineage Ventures SERVICES Global Warehousing Cold Storage Warehousing Port-Centric Warehousing Automated Warehousing Built-to-Suit Warehousing Sustainable Warehousing Fresh & Perishable Solutions Food Processing & Manufacturing Supply Ch … in the supply chain. With Lineage Ventures becoming an LP in 8VC’s most recent fund, both companies plan to increase their joint investments in cutting-edge supply chain technology start-ups, as well as support existing companies in their respective portfolios by leveraging their combined network effect and relationships. They also plan to co-develop technology together, including productizing some of Lineage’s most promising intellectual property. “As Lineage has grown, so
Lineage Cell Therapeutics and the Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor Symposium - Christopher & Dana Reeve Foundation Skip to content Click here to join Eric LeGrand at the 2026 A Walk to Believe Email Sign Up Language Español (Spanish) 中文 (Chinese) 日本語 (Japanese) 한국어 (Korean) Tiếng Việt (Vietnamese) Tagalog (Tagalog) Hebrew हिंदी (Hindi) En Francais (French) ру́сский язы́к (Russian) Português (Portuguese) Italian German Arabic Turkish Polish Bengali Urdu Swedish Connect Now National Paralysis Resource Center submit --> Donate --> Donate --> Donate … d Foundation efforts to accelerate... Read More Event: --> The Rex Marco, M.D., Fund of the Christopher & Dana Reeve Foundation Launches with $1.1M Gift Collaboration with Houston-based Spinal Surgeon Paralyzed in... Read More Event: --> A Message from the Christopher & Dana Reeve Foundation On behalf of the Christopher & Dana Reeve Foundation Board o... Read More Event: --> International Spinal Cord Injury Foundations Unite to Advance the Delivery of Spinal Cord Th … Read More Event: --> Christopher & Dana Reeve Foundation Secures Five-Year Grant for the National Paralysis Resource Center Administration for Community Living renews cooperative agree... Read More Event: --> Reeve Foundation appoints Margaret Goldberg as President and Chief Executive Officer New leadership to foster community, care and cures... Read More Event: --> Kakana and the Christopher & Dana Reeve Foundation Team Up to Support Adaptive Fitness Kakana and Ree … of Function in Spinal Cord Injuries Reeve Foundation and ISRT alliance join to fund science focu... Read More Event: --> The Christopher & Dana Reeve Foundation Marks 40 Years of Progress The Preeminent Spinal Cord Injury Nonprofit Honors Founders ... Read More Event: --> National Study Finds Limited Health Plan Coverage and High Out-of-Pocket Costs for Catheter Users People with disabilities who need catheters face significant... Read More Event: --> The Christopher &# … Resource Guide Read More Event: --> SCI Ventures Launches Venture Philanthropy Fund to Accelerate Restorative Treatments for Spinal Cord Injury and a Cure for Paralysis Read More Event: --> The Christopher & Dana Reeve Foundation Expands ‘Outdoors for Everyone’ Initiative to Address Water Accessibility As Summer Begins, ‘Outdoors for Everyon
Lineage | Portfolio Company | Hunter Search Capital Hunter Search Capital Home Entrepreneurs Portfolio Companies Our Approach About Us Resources Contact Contact Full Portfolio Lineage Lineage is focused on building plastic surgery and medical aesthetics practices. It's initial acquisition was Aesthetx, a Los Gatos, CA-based plastic surgery and medical spa provider. Sector: Healthcare Status: Portfolio Company Investment Year: 2024 Website: https://www.joinlineage.com/ https://www.aesthetx.com/d Sector: Healthcare Status: Portfolio Company Investment Year: 2024 Structure: Long Term Hold We
Forward Looking Statements – Podcasts & Recordings - Lineage Cell Therapeutics Company About Us Leadership Board of Directors Careers Contact Pipeline Overview OpRegen ® (Dry AMD) OPC1 (Spinal Cord Injury) Other Programs Technology AlloSCOPE TM Platform Manufacturing Media Investors News Events & Presentations Corporate Governance Charters and Documents Leadership Board of Directors Committee Composition Analyst Coverage Stock Information Stock Quote & Chart Historical Price Lookup Financials & Filings SEC Filings Annual Report and Proxy Information 2018 AgeX Form 10 and Inf … d activities expected to occur thereunder, its potential success, the potential application of OpRegen to additional retinal diseases, the milestone and royalty consideration payable to Lineage; the potential success of other existing partnerships and collaborations, the potential opportunities for the establishment or expansion of strategic partnerships and collaborations and the timing thereof; the projected timing of milestones of future studies, including their initiation
Error Facebook Facebook is not available on this browser To continue using Facebook, get one of the browsers below. Learn more English (US) + Meta © 2026
Facebook Explore the things you love . Log into Facebook Email or mobile number Password Log in Forgot password? Create new account English (US) فارسی العربية Türkçe Deutsch Français (France) Polski More languages… Sign Up Log In Messenger Facebook Lite Video Meta Pay Meta Store Meta Quest Ray-Ban Meta Meta AI Instagram Threads Privacy Policy Privacy Center About Create ad Create Page Developers Careers Cookies Ad choices Terms Help Contact Uploading & Non-Users Meta © 2026
Stream episode 116. Retinal restoration and visions for growth, Brian Culley, CEO, Lineage Cell Therapeutics by Biotech2050 Podcast podcast | Listen online for free on SoundCloud SoundCloud JavaScript is disabled You need to enable JavaScript to use SoundCloud Show me how to enable it 116. Retinal restoration and visions for growth, Brian Culley, CEO, Lineage Cell Therapeutics by Biotech2050 Podcast published on 2022-08-10T19:59:32Z Mr. Culley joined Lineage as Chief Executive Officer in September 2018. Prior to joining Lineage, Mr. Culley served from August 2017 to September 2018 as interim C
Spinal cord injuries affect millions—and often arrive without warning. Brian Culley, CEO of Lineage Cell Therapeutics, joins the Beyond BioTech podcast hosted by Labiotech.eu to discuss how cell therapy aims to restore function by replacing damaged cells. He also discusses challenges in cell manufacturing, the regulatory path forward, and how Lineage is working to mainstream cell therapy in vision and hearing loss. Listen now: https://bit.ly/4iYlxpi #SpinalCordInjury #SCI #RegenativeMedicine | Lineage Cell Therapeutics
Ep. 116 - Brian Culley, CEO | Lineage Cell Therapeutics — Biotech2050 Podcast Vision Episodes Newsletter Participate LP & funds Vision Episodes Newsletter Participate LP & funds Ep. 116 - Brian Culley, CEO | Lineage Cell Therapeutics Biotech 2050 Podcast · 116. Retinal restoration and visions for growth, Brian Culley, CEO, Lineage Cell Therapeutics Mr. Culley joined Lineage as Chief Executive Officer in September 2018. Prior to joining Lineage, Mr. Culley served from August 2017 to September 2018 as interim Chief Executive Officer at Artemis Therapeutics, Inc. (ATMS). Mr. Culley previous … to our newsletter and be the first to know when new episodes air. Email Address Submit Thank you! Vision Episodes Newsletter Participate
Revolutionizing Medicine with Cell Therapy: A Conversation with Brian Culley, CEO of Lineage Cell Therapeutics | Insights Podcast | Russo Partners Skip to content Menu Menu Home Capabilities Case Studies Insights News & Events Careers About Us Menu Home Capabilities Case Studies Insights News & Events Careers About Us ← Back to Insights Revolutionizing Medicine with Cell Therapy: A Conversation with Brian Culley, CEO of Lineage Cell Therapeutics October 2024 | Podcast Can cell therapy provide a real solution for spinal cord injuries, as well as vision and hearing loss? In this episode,
On the Oracles of Eye... - Lineage Cell Therapeutics Facebook Log In Lineage Cell Therapeutics's Post Lineage Cell Therapeutics September 4, 2025 · Shared with Public On the Oracles of Eye Innovation podcast hosted by Medevise, Brian Culley, CEO of Lineage Cell Therapeutics , shares how the company is advancing cell therapies for treating geographic atrophy from dry AMD. Brian explains why cell transplantation is emerging as a powerful approach in ophthalmology and how Lineage is tackling the challenge of manufacturing at scale. Apple Podcasts: https://apple.co/4pcGIHI Spotify: https://bi
Lineage Establishes New R&D Facility in U.S. and Expands Current GMP Manufacturing Facility in Israel - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cel … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Lineage Establishes New R&D Facility in U.S. and Expands Current GMP Manufacturing Facility in Israel October 3, 2022 | 7 min read Twitter LinkedIn Facebook Email Print Lineage Cell Therapeutics, Inc. announced the opening of a new research and development facility in Carlsbad, California … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Lineage Cell Therapeutics Issues Letter to Stockholders - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Lineage Cell Therapeutics Issues Letter to Stockholders January 7, 2025 | 16 min read Twitter LinkedIn Facebook Email Print CARLSBAD, Calif.--(BUSINESS WIRE)-- $LCTX #LineageCellTherapeutics -- Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developin … h the advancement of our clinical and preclinical pipelines, where we intend to apply our technology and expertise to validate our unique cell transplant approach. We appreciate your support and belief in our vision. We invite you to stay engaged with our progress through regular updates, earnings calls, and announcements. Replace and Restore, Brian Culley, CEO Lineage Cell Therapeutics, Inc. About Lineage Cell Therapeutics, Inc. Lineage Cell Therapeutics is a clinical-stage … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Lineage Cell Therapeutics Initiates Cell Transplant Program In Type 1 Diabetes - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer O … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Lineage Cell Therapeutics Initiates Cell Transplant Program In Type 1 Diabetes September 9, 2025 | 7 min read Twitter LinkedIn Facebook Email Print Initial Program Focus Will Be On Addressing Manufacturing Scale CARLSBAD, Calif.--(BUSINESS WIRE)-- $LCTX #LineageCellTherapeutics -- Lineage Cell Therapeutic … asibility decision on this initiative with a fairly modest investment, but also apply any relevant insights or improvements to our other transplant programs, including programs we may launch in the future. Overall, if we are successful in developing a commercially-viable production modality for islet cells, we believe it will create a compelling product profile, as well as provide options to license this technology to a partner or enter the diabetes field directly.” About Typ … s include, but are not limited to, statements relating to: Lineage’s ability to apply its manufacturing capabilities to establish a production modality that can address the issues of large-scale production of islet cells, and that such capability can produce doses of hundreds of millions of cells per patient; the potential application of any such production modality achievements to a hypo-immune cell line that is suitable to support a clinical T1D program and/or any other cur … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Lineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Lineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update May 13, 2026 | 20 min read Twitter LinkedIn Facebook Email Print Positive 3 Year Phase 1/2a Clinical Data of RG6501 (OpRegen®) Featured at Retinal Therapeutics Innovation Summit 2026 Launched New Corneal En … xisting ophthalmology and manufacturing expertise and represents a natural next application of our platform. We also achieved our first milestone with our AlloSCOPE 5D manufacturing initiative, aimed at addressing the challenges of large scale production of undifferentiated pluripotent stem cells. If successful at a larger scale, the overall goal is to leverage this initiative, together with a differentiation protocol, to address the insufficient supply of islet cells needed … xisting ophthalmology and manufacturing expertise and represents a natural next application of our technology platform. Applicable indications for COR1 are expected to include Fuchs Endothelial Corneal Dystrophy (FECD) and Bullous Keratopathy. Utilizing Lineage’s proprietary cell manufacturing and expansion platform, AlloSCOPE™ , the Company is manufacturing “off the shelf” corneal endothelial cells with identity, morphological, and functional characteristics which meet initi … terial for two final cell-based product candidates. AlloSCOPE “5D” describes an application of AlloSCOPE with the goal of higher scale production with reduced manipulation. About Lineage Cell Therapeutics, Inc. Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell therapies for s
Lineage Cell Therapeutics Reinitiates Patient Enrollment in Clinical Study of OpRegen® for the Treatment of Dry AMD With Geographic Atrophy - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufactu … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development Lineage Cell Therapeutics Reinitiates Patient Enrollment in Clinical Study of OpRegen® for the Treatment of Dry AMD With Geographic Atrophy June 18, 2020 | 8 min read Twitter LinkedIn Facebook Email Print Lineage Cell Therapeutics Reinitiates Patient Enrollment in Clinical Study of Op … principal investigator Christopher D. Riemann , M.D., Vitreoretinal Surgeon and Fellowship Director, CEI and University of Cincinnati School of Medicine. CEI is a global leader in ophthalmology research and a clinical site where local health and safety regulations recently enabled and cleared clinical study recruitment and treatment. The patient enrolled at CEI was administered Lineage’s new thaw-and-inject formulation of OpRegen with Gyroscope Therapeutics’ Orbit Subretinal … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Lineage Cell Therapeutics to Present at September 2025 Investor Conferences - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opin … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Lineage Cell Therapeutics to Present at September 2025 Investor Conferences September 3, 2025 | 2 min read Twitter LinkedIn Facebook Email Print H.C. Wainwright 27 th Annual Global Investment Conference Presentation on September 8, 2025 Baird's 2025 Global Healthcare Conference Presentation on September 9 … bsp; 2 min read · Tristan Manalac Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst China BIO 2026: US needs to dodge China’s ‘inescapable dependencies’ to protect biotech June 24, 2026 · 2 min read · Annalee Armstrong BioSpace at BIO to find out" href="https://www.biospace.com/drug-development/can-adcs-be-kin … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin